ArticleJournal of public health in Africa2025
The use of lateral flow lipoarabinomannan for diagnosis of TB in advanced HIV disease in Abia State, Nigeria.
Article in Journal of public health in Africa, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lateral flow lipoarabinomannan (LF-LAM) test used in the diagnosis of active tuberculosis (TB) among patients with advanced human immunodeficiency virus (HIV) disease remains a relatively new approach in the diagnosis of TB in Nigeria. This study focused on the use of LF-LAM assay Alere Determine™ in the diagnosis of active tuberculosis among patients with advanced HIV disease in Abia State. Aim: This study was carried out to identify potential gaps that could be missed along the LF-LAM implementation cascade, which can be strengthened to improve quality of patients' care, while gaining insight into health workers' understanding of the test. Setting: This study was carried out in Abia State, Nigeria. Methods: Electronic data were extracted through a query run on health facility electronic databases, while manual chart abstraction was performed in facilities without and incomplete electronic medical records. In addition, qualitative interviews were conducted among health workers to gain insight. Results: Out of 1249 newly enrolled patients who were eligible for the test, only 605 (48.4%) were tested, and 644 (51.6%) were missed within the study period (October 2022 - September 2023). Out of this number, 159 (26.3%) were positive for the test, and only 68 (42%) were sent for further testing with GeneXpert, while 30 (18.9%) had no testing with GeneXpert and 61 (38.9%) had no documentation. Conclusion: Low awareness and capacity among health workers including poor documentation practices contributed to missed opportunities for the patients who could have benefitted from this test. Contribution: The study recommends comprehensive training of healthcare workers on the utilisation of LF-LAM test and improvement of documentation practices in Abia State and Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.